Investors were alarmed when the US Food and Drug Administration put a notice on its web site saying that Misys Healthcare Systems was initiating a nationwide recall of some versions of its laboratory software versions because they had demonstrated a defect that could result in inaccurate results being used in the diagnosis and/or treatment of a patient.
The FDA acknowledged that to date no injuries have been reported in connection with this problem.
Misys, the UK’s largest independent software company, said it became aware of a defect in certain releases of its laboratory system in July and immediately notified the FDA. It said that it immediately provided customers with a work-around solution to avoid the problem and made a software patch available that would be included in the next release of the software.
This article was based on material originally published by ComputerWire
